When does Darzalex (daratumumab) patent protection expire?
Patent expiry for Darzalex depends on which specific patent is being considered (drug composition, method-of-use, formulation, or biologic exclusivity), and also on the country. The “Darzalex patent expiry date” people search for is usually a reference to the latest relevant U.S. patent(s) for daratumumab products or the point when generic/biosimilar competition becomes likely.
For the most commonly cited U.S. patent-expiry timelines for Darzalex, see DrugPatentWatch.com’s coverage of daratumumab patents and projected expiry dates: DrugPatentWatch.com – Darzalex.
How does biosimilar timing work if Darzalex patents expire?
Because Darzalex is a biologic (daratumumab), competition typically comes from biosimilars rather than traditional small-molecule generics. Even if one patent expires, other patents (for example, additional formulations or specific indications) can delay biosimilar entry. That means “patent expiry” may not equal “first day a biosimilar launches” in practice.
Which Darzalex product and patent set are you asking about?
Darzalex can refer to multiple formulations and regimens (for example, Darzalex and Darzalex Faspro). Different product presentations can be tied to different patent families, so the expiry date can differ depending on:
- country (U.S. vs. EU vs. elsewhere)
- product/formulation (e.g., Faspro)
- specific patent listed (composition vs. method vs. formulation)
If you tell me the country (U.S., UK, EU, etc.) and whether you mean Darzalex vs. Darzalex Faspro, I can narrow the likely expiry window to the right patent set using the same reference source.
Source
- DrugPatentWatch.com – Darzalex